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Abstract
The association of the anti-anginal drug nicorandil with oral and anal ulceration is becoming more widely recog-
nised, but there are no reports of isolated nicorandil-induced rectal ulceration. Awareness of this condition is poor,
and patients often undergo unnecessary surgery for a condition which resolves on stopping the medication.
We report a case of nicorandil-induced rectal ulceration causing rectal bleeding. The patient was spared surgery
after awareness of the link with this drug.
This diagnosis should be considered in patients with unexplained gastrointestinal ulceration after exclusion of
serious underlying causes. We hope this report will increase awareness amongst physicians and surgeons of this
reversible condition.
Background
Nicorandil, a nicotinamide ester, was originally intro-
duced in Japan in 1984 and subsequently launched in
Europe ten years later. Acting as both a venodilator and
arteriolar vasodilator, it reduces cardiac preload and
afterload, and increases coronary blood flow [1]. It is
widely used as a second-line medication in the preven-
tion and long-term treatment of angina. In 2002 a land-
mark randomised controlled trial, the IONA study,
showed that as well as providing symptomatic benefit
nicorandil also had cardioprotective properties [2]. Since
then, it has been widely prescribed and is particularly
useful in patients with refractory or unstable angina.
Common side-effects of nicorandil therapy include
headaches, flushing, nausea and dizziness, but more
recently a number of reports have linked its use with
oral [3], anal [4], vulval and parastomal ulceration [5], as
well as anal fistulation [6] (see Appendix 1). However,
there are currently no reports in the English literature
linking nicorandil therapy with ulceration of the rectum.
Furthermore, there is still a lack of awareness of nicor-
andil-induced ulceration, and consequently this diag-
n o s i si so f t e no v e r l o o k e d .W ep r e s e n tac a s eo fr e c t a l
bleeding secondary to nicorandil-induced rectal ulcera-
tion and aim to increase awareness of this reversible
condition.
Case presentation
An 80 year-old man with a background history of pros-
tate cancer, requiring radiotherapy in 2003, was
admitted under the surgical team in 2009 with recurrent
episodes of fresh rectal bleeding which began 3 years
earlier. He had numerous admissions since 2006, and
investigation with flexible sigmoidoscopy and an abdom-
inal CT scan at that time showed multiple telangiectasia
and diverticular disease. He was diagnosed with radia-
tion proctitis and underwent argon beam therapy How-
ever, this failed to improve his symptoms and in 2008
he developed worsening rectal bleeding. He had been
a d v i s e dt ot r ys t e r o i de n e m a s ,b u tt h i sd i d n ’th a v ea n y
effect.
He had a history of severe ischaemic heart disease for
which he had a coronary artery bypass graft, and after a
subsequent myocardial infarction underwent coronary
angioplasty and stent insertion. Despite this, he contin-
ued to have angina, and so was started on nicorandil
10 mg twice daily in 2006. Of note, in 2008, his nicoran-
dil dose was increased to 30 mg twice daily, and it was a
few months after this that his rectal bleeding worsened. * Correspondence: sachmalde@aol.com
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flexible sigmoidoscopy. This revealed a large area of
ulceration with well-defined margins on the anterior
rectal wall. Biopsies were taken and histology showed
non-specific inflammation with no evidence of
malignancy.
In view of the ongoing bleeding, he was listed for
abdomino-perineal excision of the rectum, but we
became aware of the link with nicorandil, and so the
surgery was deferred. The nicorandil was discontinued
after discussion with a cardiologist, and over the follow-
ing weeks the patient’s symptoms resolved. The ulcera-
tion healed completely and has not recurred since. He
remains under close cardiology follow-up to ensure
there is no deterioration in his anginal symptoms.
Discussion
Rectal bleeding is a common surgical complaint and has
a multitude of causes. Any patient presenting with this
symptom should be fully investigated to identify the
underlying cause. Ulceration of the rectal mucosa may
cause bleeding, and itself may be the result of various
disease processes including malignant and inflammatory
conditions. Treatment will vary widely depending upon
the cause and so biopsy of any ulceration is essential to
aid diagnosis and therefore treatment. More serious
underlying causes for rectal ulceration should be
excluded before implicating nicorandil.
Reports of nicorandil-induced ulceration first appeared
i nt h eF r e n c hl i t e r a t u r ei n1 9 9 7[ 7 ] ,a n ds i n c et h e nt h e
number of identified cases has increased. Oral and anal
ulceration has been well described, but more recently
associations with the gastrointestinal tract have docu-
mented. Nicorandil-induced perforation of the terminal
ileum has been reported [8], as well as recent reports of
multiple synchronous colonic ulcers either in isolation
or in combination with anal ulcers [9]. Oesophageal
ulceration has also been reported [10] suggesting that
any part of the GI tract can be involved. Rectal ulcera-
tion, however, has never been reported. As in our case,
ulcers are typically described as large punched-out
lesions which characteristically show complete resolu-
tion on discontinuation of the drug, and biopsy will
show non-specific inflammation only. They may occur
as early as 2 months after starting nicorandil therapy,
but have even been reported 36 months later [11].
The mechanism by which it causes ulceration is not
completely understood but suggestions include a direct
local effect of nicorandil or one of its metabolites, or a
‘vascular steal phenomenon’. A vascular steal phenom-
enon occurs in vascular beds in which one portion is sup-
plied by a patent artery and the other by a stenosed
artery, in a setting of generalised vasodilatation. As the
stenosed artery is already maximally dilated in
compensation for the distal narrowing, use of vasodila-
tory drugs will cause blood to flow preferentially to the
patent artery, resulting in ischaemia in the territory sup-
plied by the stenosed artery. An interesting feature of this
particular case is the fact that the patient has chronic
radiation proctitis. Radiation damage results in focal
destruction of arterioles, intimal fibrosis and mucosal
ischaemia. It is likely, therefore, that the use of nicorandil
caused a reduction in blood flow to the areas affected by
radiation damage due to a vascular steal phenomenon,
resulting in further mucosal ischaemia and subsequent
ulceration. The fact that only the rectum was involved in
this case further supports this putative mechanism, sug-
gesting that patients with radiation proctitis are at an
increased risk of nicorandil-induced ulceration. This
should be borne in mind when prescribing this drug.
Whatever the mechanism, it has been suggested that
the effect is dose-dependent. The majority of cases are
reported in patients taking 40-60 mg daily and it has
been found that reducing the dose can improve ulcer
healing [12]. Despite this, there have been reports of
ulceration in patients taking 10 mg/day [13]. Although
treatment with colchicine, thalidomide and prednisolone
has been tried [11], ulcers frequently recur. The only
definitive treatment is discontinuation of the drug, and
complete ulcer healing can take anywhere between
2 weeks to 10 months. This should only be done under
supervision by a cardiologist, however, as these patients
are at high-risk of recurrence of anginal symptoms. The
Medicines and Healthcare Products Regulatory Agency
emphasises this point, and patients should remain under
close cardiology follow-up to ensure there is no dete-
r i o r a t i o ni nt h ep a t i e n t ’s anginal symptoms. If it cannot
be discontinued, reducing the dose may improve ulcer
healing sufficiently to ease symptoms.
The importance of recognising this condition is that it
is reversible upon stopping the medication, and will
avoid unnecessary surgery in patients with significant
co-morbidities. There have been reports of patients
undergoing diversion colostomies for ulceration [14],
but the ulcers often recur. In our case, the patient had
been listed for abdomino-perineal resection of the rec-
tum, but was spared this major surgery after we became
aware of the possible link with nicorandil. The value of
a good history cannot be overemphasised. Our patient
was repeatedly diagnosed with radiation proctitis given
his past history. On careful questioning however, it was
found that his symptoms worsened a few months after
starting high-dose nicorandil therapy. This eventually
led to the diagnosis in this case.
Conclusion
Nicorandil therapy is becoming increasingly recognised
as a cause of gastrointestinal ulceration and it should
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condition. Ulceration resolves completely on withdrawal
of the drug, although this should only be done in con-
junction with a cardiologist. Awareness of this condition
will prevent unnecessary and major surgery in this high-
risk group of patients.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompany-
ing images. A copy of the written consent is available
for review by the Editor-in-Chief of this journal.
Appendix 1
Reported side-effects of nicorandil by likelihood of
occurrence
Very common (affect 1 in 10 people)
Headaches
Common (affect between 1 in 10 to 1 in 100
people)
Dizziness
Nausea and vomiting
Flushing of the skin
Uncommon (affect between 1 in 100 and 1 in 1000
people)
Low blood pressure
Increased heart rate
Mouth ulcers
Pain in your muscles
Angioedema
Rare (affect between 1 in 1000 and 1 in 10,000
people)
Skin rashes
Abnormal liver function causing jaundice
Very rare (affect less than 1 in 10,000 people)
Ulcers- Stomach, colon, rectum, anus, genital tract,
nasal passages, peri-stomal
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